Menu
Search Close

News

Appointment of Broker

06th September 2010

The Board of Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, announce the appointment of Matrix Corporate Capital LLP as joint broker with immediate effect.

For further information contact:

Professor Lindy Durrant - Scancell Holdings Plc

  • + 44 (0)207 245 1100

John Bick/Kirsty Corcoran - Hansard Communications

  • + 44 (0)207 245 1100

Ross Andrews/Tom Rowley - Zeus Capital - Nominated Adviser/Joint Broker

  • + 44 (0)161 831 1512

Robert Naylor/Stephen Waterman - Matrix Corporate Capital LLP - Joint Broker

  • +44 (0)20 3206 7340

View the full Document

Webcasts, Interviews and Media Coverage

Scancell to begin dosing in UK phase II trial of flagship skin cancer drug

Cliff Holloway, CEO of Scancell Holdings PLC (LON:SCLP), speaks to Proactive London's Andrew Scott after announcing they're to kick off the UK arm of the phase II clinical trial of its flagship skin cancer drug.

The study will test the safety and efficacy of SCIB1 in 25 metastatic melanoma patients who are also receiving Merck’s checkpoint inhibitor Pembrolizumab.

Thu, 25 Apr 2019 10:56:00

Scancell higher as it is to begin UK arm of phase II skin cancer trial within weeks

The mid-stage study is testing Scancell’s flagship skin cancer immunotherapy in combination with Keytruda – the blockbuster checkpoint inhibitor developed by Merck

Thu, 25 Apr 2019 12:20:00

Scancell Holdings wins Japanese patent protection

It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia

Mon, 08 Apr 2019 08:20:00